Chotaro Onaga
Chiba, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Luminal B Breast Cancer Coexpressing p62 and ALDH1A3 Is Less Susceptible to Radiotherapy.
Journal: Anticancer research
Published: October 27, 2023
Co‑expression of SLC20A1 and ALDH1A3 is associated with poor prognosis, and SLC20A1 is required for the survival of ALDH1‑positive pancreatic cancer stem cells.
Journal: Oncology letters
Published: July 23, 2023
High SLC20A1 Expression Indicates Poor Prognosis in Prostate Cancer.
Journal: Cancer diagnosis & prognosis
Published: April 07, 2023
High Expression of CD58 and ALDH1A3 Predicts a Poor Prognosis in Basal-like Breast Cancer.
Journal: Anticancer research
Published: August 07, 2022
High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer.
Journal: Cancer diagnosis & prognosis
Published: May 09, 2022
High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
Journal: Anticancer research
Published: May 09, 2022
GLO 1 and PKCλ Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
Journal: Anticancer research
Published: September 11, 2021
High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers.
Journal: Anticancer research
Published: November 12, 2020
Glyoxalase 1 and protein kinase Cλ as potential therapeutic targets for late-stage breast cancer.
Journal: Oncology letters
Published: September 02, 2020
High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.
Journal: PloS one
Published: November 27, 2019
High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer.
Journal: Anticancer research
Published: November 13, 2019
Last Updated: 09/26/2026